Viewing Study NCT00000646



Ignite Creation Date: 2024-05-05 @ 9:36 AM
Last Modification Date: 2024-10-26 @ 9:02 AM
Study NCT ID: NCT00000646
Status: COMPLETED
Last Update Posted: 2021-11-02
First Post: 1999-11-02

Brief Title: Pentoxifylline Trental as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS
Sponsor: National Institute of Allergy and Infectious Diseases NIAID
Organization: National Institute of Allergy and Infectious Diseases NIAID

Study Overview

Official Title: Pentoxifylline Trental as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS
Status: COMPLETED
Status Verified Date: 2021-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To determine whether pentoxifylline lowers tumor necrosis factor TNF levels in AIDS patients Pentoxifylline decreases tumor necrosis factor TNF and therefore should decrease such TNF-intensified events as cachexia enhanced HIV expression and inhibition of zidovudine AZT activity
Detailed Description: Pentoxifylline decreases tumor necrosis factor TNF and therefore should decrease such TNF-intensified events as cachexia enhanced HIV expression and inhibition of zidovudine AZT activity

Twenty-seven AIDS patients with elevated TNF and less than 300 CD4 cells are given pentoxifylline 3 times a day for 8 weeks If no significant changes are seen in virologic immunologic or related measures 27 additional patients are given a higher dose of pentoxifylline 3 times a day for eight weeks

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
Secondary ID Type Domain Link
11135 REGISTRY DAIDS ES Registry Number None